2. Disease Areas
  3. Inflammation or Immune System Disease Respiratory Disease
  4. Respiratory Inflammation Lower Respiratory Inflammation
  5. Bronchitis

Bronchitis

Bronchitis is an inflammation of the bronchial tubes, characterized by coughing, mucus production, and associated symptoms such as shortness of breath, wheezing, low fever, and chest tightness. It may be acute or chronic, with acute bronchitis commonly caused by viral infections like those responsible for colds and flu, though bacterial infections can also trigger it. Treatment focuses on rest, hydration, and symptomatic relief using medications like aspirin or acetaminophen for fever; antibiotics are only prescribed when a bacterial cause is confirmed. Most cases resolve within a few weeks without specific treatment.

References:

Bronchitis (6):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-171333
    TMEM16A modulator-1 2367645-32-5
    TMEM16A modulator-1 (compound 36) is a positive modulator of the calcium-activated chloride channel (CaCC) TMEM16A. TMEM16A modulator-1 can be used for TMEM16A-related diseases research, particularly respiratory diseases and conditions.
    TMEM16A modulator-1
  • HY-172242
    Verducatib 1887236-33-0 98.94%
    Verducatib (BI 1291583) is an orally active inhibitor of cathepsin C (also known as DPP1). Verducatib restores the protease-inhibitor balance by inhibiting the activation of neutrophil serine proteases, thereby alleviating pulmonary inflammation and regulating infection responses. Verducatib significantly reduces the risk (including severe exacerbations) and frequency of acute exacerbations in bronchiectasis (BE). Verducatib also improves lung function and quality of life, and shortens the duration of antibiotic use. The overall incidence of adverse events of Verducatib is comparable to that of placebo, with only slightly more mild-to-moderate cutaneous adverse events observed in the high-dose group, demonstrating promising clinical application potential.
    Verducatib
  • HY-182724
    PSB-18422 2244978-64-9
    PSB-18422 is a GPR17 agonist, with an EC50 of 0.0279 μM for humans, 0.47 μM for rats, 0.753 μM for mice, and a human Ki of 1.46 μM. PSB-18422 triggers intracellular calcium mobilization via cross-species activation of GPR17. PSB-18422 can be used in the research of allergic bronchial inflammation.
    PSB-18422
  • HY-N9741
    (+)-Nyasol 185020-38-6
    (+)-Nyasol is a stilbene-type organic compound that can be naturally extracted from the dried roots of Asparagus filicinus Ham. ex D. Don (an Asparagus species) from Fenna, Tibet, China. This plant is traditionally used in the study of bronchitis, cough, and pneumonia, and can be used in research related to respiratory diseases.
    (+)-Nyasol
  • HY-105026
    Cistinexine 86042-50-4
    Cistinexine is a new expectorant agent. Cistinexine interacts with the complex form of RdRp. Cistinexine can be used in the study of chronic bronchitis. RdRp is involved in the replication and transcription of the SARS-CoV-2 genome.
    Cistinexine
  • HY-W746270
    Guaimesal 81674-79-5
    Guaimesal is a new antiphlogistic and mucus-regulating agent. Guaimesal improves bronchitis symptoms.
    Guaimesal